153 related articles for article (PubMed ID: 37174717)
1. Extracellular Vesicle-Packaged miR-195-5p Sensitizes Melanoma to Targeted Therapy with Kinase Inhibitors.
Santos NL; Bustos SO; Reis PP; Chammas R; Andrade LNS
Cells; 2023 May; 12(9):. PubMed ID: 37174717
[TBL] [Abstract][Full Text] [Related]
2. BRAF
Lunavat TR; Cheng L; Einarsdottir BO; Olofsson Bagge R; Veppil Muralidharan S; Sharples RA; Lässer C; Gho YS; Hill AF; Nilsson JA; Lötvall J
Proc Natl Acad Sci U S A; 2017 Jul; 114(29):E5930-E5939. PubMed ID: 28684402
[TBL] [Abstract][Full Text] [Related]
3. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators.
Vergani E; Dugo M; Cossa M; Frigerio S; Di Guardo L; Gallino G; Mattavelli I; Vergani B; Lalli L; Tamborini E; Valeri B; Gargiuli C; Shahaj E; Ferrarini M; Ferrero E; Gomez Lira M; Huber V; Del Vecchio M; Sensi M; Leone BE; Santinami M; Rivoltini L; Rodolfo M; Vallacchi V
Cell Commun Signal; 2020 Sep; 18(1):156. PubMed ID: 32967672
[TBL] [Abstract][Full Text] [Related]
4. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma.
Díaz-Martínez M; Benito-Jardón L; Alonso L; Koetz-Ploch L; Hernando E; Teixidó J
Cancer Res; 2018 Feb; 78(4):1017-1030. PubMed ID: 29229605
[TBL] [Abstract][Full Text] [Related]
5. Conjunctival malignant melanoma in Denmark: epidemiology, treatment and prognosis with special emphasis on tumorigenesis and genetic profile.
Larsen AC
Acta Ophthalmol; 2016 May; 94 Thesis 1():1-27. PubMed ID: 27192168
[TBL] [Abstract][Full Text] [Related]
6. In Vitro Biophysical and Biological Characterization of Lipid Nanoparticles Co-Encapsulating Oncosuppressors miR-199b-5p and miR-204-5p as Potentiators of Target Therapy in Metastatic Melanoma.
Fattore L; Campani V; Ruggiero CF; Salvati V; Liguoro D; Scotti L; Botti G; Ascierto PA; Mancini R; De Rosa G; Ciliberto G
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32178301
[TBL] [Abstract][Full Text] [Related]
7. BRAFi induced demethylation of miR-152-5p regulates phenotype switching by targeting TXNIP in cutaneous melanoma.
Li K; Tang M; Tong S; Wang C; Sun Q; Lv M; Sun X; Wang T; Jin S
Apoptosis; 2020 Apr; 25(3-4):179-191. PubMed ID: 32056038
[TBL] [Abstract][Full Text] [Related]
8. miR-524-5p reduces the progression of the BRAF inhibitor-resistant melanoma.
Nguyen MT; Lin CH; Liu SM; Miyashita A; Ihn H; Lin H; Ng CH; Tsai JC; Chen MH; Tsai MS; Lin IY; Liu SC; Li LY; Fukushima S; Lu J; Ma N
Neoplasia; 2020 Dec; 22(12):789-799. PubMed ID: 33142243
[TBL] [Abstract][Full Text] [Related]
9. Impact of BRAF kinase inhibitors on the miRNomes and transcriptomes of melanoma cells.
Kozar I; Cesi G; Margue C; Philippidou D; Kreis S
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt B):2980-2992. PubMed ID: 28408301
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive Analyses of miRNAs Revealed miR-92b-3p, miR-182-5p and miR-183-5p as Potential Novel Biomarkers in Melanoma-Derived Extracellular Vesicles.
Gerloff D; Kewitz-Hempel S; Hause G; Ehrenreich J; Golle L; Kingreen T; Sunderkötter C
Front Oncol; 2022; 12():935816. PubMed ID: 35898875
[TBL] [Abstract][Full Text] [Related]
11. miR-224-5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway.
Liu Y; Ruan H; Lu F; Peng H; Luan W
Pathol Res Pract; 2023 Sep; 249():154772. PubMed ID: 37611431
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF
Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ
J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955
[TBL] [Abstract][Full Text] [Related]
13. miR-579-3p controls melanoma progression and resistance to target therapy.
Fattore L; Mancini R; Acunzo M; Romano G; Laganà A; Pisanu ME; Malpicci D; Madonna G; Mallardo D; Capone M; Fulciniti F; Mazzucchelli L; Botti G; Croce CM; Ascierto PA; Ciliberto G
Proc Natl Acad Sci U S A; 2016 Aug; 113(34):E5005-13. PubMed ID: 27503895
[TBL] [Abstract][Full Text] [Related]
14. miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.
Choe MH; Yoon Y; Kim J; Hwang SG; Han YH; Kim JS
Cell Death Dis; 2018 May; 9(6):640. PubMed ID: 29844307
[TBL] [Abstract][Full Text] [Related]
15. Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance.
Fattore L; Cafaro G; Di Martile M; Campani V; Sacconi A; Liguoro D; Marra E; Bruschini S; Stoppoloni D; Cirombella R; De Nicola F; Pallocca M; Ruggiero CF; Castaldo V; Catizone A; Del Bufalo D; Viglietto G; Vecchione A; Blandino G; Aurisicchio L; Fanciulli M; Ascierto PA; De Rosa G; Mancini R; Ciliberto G
Oncogene; 2023 Jan; 42(4):293-307. PubMed ID: 36418472
[TBL] [Abstract][Full Text] [Related]
16. Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.
Svedman FC; Lohcharoenkal W; Bottai M; Brage SE; Sonkoly E; Hansson J; Pivarcsi A; Eriksson H
PLoS One; 2018; 13(11):e0206942. PubMed ID: 30399176
[TBL] [Abstract][Full Text] [Related]
17. The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors.
Liguoro D; Frigerio R; Ortolano A; Sacconi A; Acunzo M; Romano G; Nigita G; Bellei B; Madonna G; Capone M; Ascierto PA; Mancini R; Ciliberto G; Fattore L
Cell Death Dis; 2024 Mar; 15(3):208. PubMed ID: 38472212
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cell-derived extracellular vesicles transfer miR-182-5p and promote breast carcinogenesis via the CMTM7/EGFR/AKT axis.
Lu C; Zhao Y; Wang J; Shi W; Dong F; Xin Y; Zhao X; Liu C
Mol Med; 2021 Jul; 27(1):78. PubMed ID: 34294040
[TBL] [Abstract][Full Text] [Related]
19. microRNA-148a-3p in extracellular vesicles derived from bone marrow mesenchymal stem cells suppresses SMURF1 to prevent osteonecrosis of femoral head.
Huang S; Li Y; Wu P; Xiao Y; Duan N; Quan J; Du W
J Cell Mol Med; 2020 Oct; 24(19):11512-11523. PubMed ID: 32871042
[TBL] [Abstract][Full Text] [Related]
20. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
